Show simple item record

dc.contributor.authorMorrissey, Hana
dc.contributor.authorBall, Patrick
dc.contributor.authorAhmed, Ari
dc.contributor.authorIbrahim, Rangeen
dc.contributor.authorAbadie, Mohammed
dc.date.accessioned2019-05-30T13:30:07Z
dc.date.available2019-05-30T13:30:07Z
dc.date.issued2019-04-28
dc.identifier.citationAbadie, M. et al. Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre, International Journal of Current Medical And Pharmaceutical Research, Vol. 5, Issue, 04(A), pp. 4114-4118, April, 2019en
dc.identifier.doi10.24327/23956429.ijcmpr201904635en
dc.identifier.urihttp://hdl.handle.net/2436/622380
dc.description.abstractA clinical pathway was created to feed information into a clinical audit checklist, and was adopted as the patient-management model for biological therapies. From this, the data was reviewed concerning 41 patients who were receiving SEC between January 2014 and December 2018. The results for the Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) score which are typically reviewed at baseline and at 16 weeks to assess response to treatment.en
dc.formatapplication/PDFen
dc.languageEnglish
dc.language.isoenen
dc.publisherInternational Journal Of Current Medical And Pharmaceutical Researchen
dc.subjectSecukinumaben
dc.subjectbiologic therapiesen
dc.subjectPsoriasis Area Severity Indexen
dc.subjectPASIen
dc.subjectDermatology Life Quality Indexen
dc.subjectDLQIen
dc.titleContinuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centreen
dc.typeJournal articleen
dc.identifier.journalInternational Journal Of Current Medical And Pharmaceutical Researchen
dc.date.updated2019-05-20T07:48:33Z
dc.date.accepted2019-03-23
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW3005HMen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2019-05-30en
dc.source.volume5
dc.source.issue4
dc.source.beginpage4162
dc.source.endpage4164
refterms.dateFCD2019-05-30T13:26:44Z
refterms.versionFCDVoR
refterms.dateFOA2019-05-30T13:30:07Z


Files in this item

Thumbnail
Name:
Continuation of therapy of ...
Size:
362.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record